Benepali, Imraldi and Flixabi. [Photo provided by Samsung Bioepis]
Samsung Bioepis generated $390 million in sales from its three biosimilars (Benepali, Flixabi, and Imraldi) across Europe in the first half of this year, gaining around 9 percent from a year ago, the company said on Thursday.
Sales in the second quarter in Europe declined 7 percent on year to $171.6 million due to the impact of the COVID-19 pandemic, compared with 24 percent jump to $218.8 million in the first quarter.
Samsung Bioepis said its market share in Europe continues to rise despite the pandemic and growing competition from rival products.
The company’s stalwart product is Benepali (etanercept), which is the first Enbrel biosimilar launched in Europe. Benepali already narrowed the gap with its reference drug to below 1 percent as of April based on its first-mover position. Benepali’s cumulative sales to date since its launch in the first quarter of 2016 have reached $1.68 billion.
In the Humira (adalimumab) biosimilar market, where five brands are pitting against each other, Samsung Bioepis’ Imraldi controls more than 30 percent of the sector.
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]